Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC), a clinical-stage biotechnology firm, announced participation in two key investor conferences. The H.C. Wainwright Cell Therapy Virtual Conference will feature a fireside chat on February 28, 2023, at 10:30 AM ET. Additionally, the Cowen 43rd Annual Health Care Conference presentation is set for March 6, 2023, at 11:10 AM ET. Replays of both events will be accessible for 30 days via the company's website's “Events & Presentations” section. Century Therapeutics focuses on developing induced pluripotent stem cell-derived therapies to improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) has announced that the first patient has been dosed in the Phase 1 ELiPSE-1 trial of CNTY-101, a novel allogeneic cell therapy targeting relapsed or refractory CD19-positive B-cell lymphomas. This investigational therapy incorporates six precision gene edits, including a CD19 CAR and Allo-Evasion™ technology, designed to overcome immune rejection. The trial aims to assess CNTY-101's safety, tolerability, and preliminary efficacy through a unique multi-dosing strategy, potentially paving the way for innovative cell therapy treatments.
On February 1, 2023, Century Therapeutics (NASDAQ: IPSC) announced its participation in two upcoming investor conferences. The first event, The Guggenheim Healthcare Talks Oncology Day, is scheduled for February 8, 2023, at 3:55 PM ET. The second, The SVB Securities Global Biopharma Conference, will take place on February 15, 2023, at 11:20 AM ET. A replay of these events will be available on the company’s website for 30 days following the conferences. Century Therapeutics is focused on developing iPSC-derived cell therapies for cancer treatment, aiming to improve patient access and outcomes in oncology.
Century Therapeutics (NASDAQ: IPSC) has announced a strategic portfolio prioritization aimed at extending its cash runway into 2026. The company will focus on CNTY-101 for relapsed/refractory B-cell lymphoma and CNTY-107 for Nectin-4+ tumors, while de-prioritizing CNTY-103 for glioblastoma. A workforce reduction of approximately 25% has been implemented to support this strategy. The Phase 1 study of CNTY-101 remains on track, with no impact on the partnered programs with Bristol Myers Squibb. CEO Lalo Flores emphasizes the importance of these changes for achieving key development milestones.
Century Therapeutics (NASDAQ: IPSC) will have its CEO, Lalo Flores, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 AM PT. As a biotechnology company specializing in iPSC-derived cell therapies for cancer treatment, Century aims to address the limitations of traditional therapies. A live webcast of the presentation will be available on their website, with a replay accessible for a limited time. For more company insights, visit Century Therapeutics.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 2:00 PM ET. A live webcast of the event will be accessible on the company's website, with an archived replay available for a limited time. The company focuses on developing iPSC-derived cell therapies to address cancer, leveraging advanced cellular reprogramming and genetic engineering. Their goal is to create off-the-shelf cell therapies that enhance patient access and improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) announced significant preclinical advancements in its iPSC-derived cell therapy platform, showcased at the SITC 37th Annual Meeting. Key highlights include effective anti-tumor activity of iPSC-derived CAR gamma delta T cells and the nomination of CNTY-107, targeting Nectin-4 for solid tumors, with an IND filing expected in 2025. The company is enhancing its iNK cell platform, focusing on genetic modifications for improved efficacy and safety. Century is set to provide further insights during a virtual R&D Day on November 11, 2022.
Century Therapeutics (NASDAQ: IPSC) reported its third-quarter 2022 results, revealing a cash position of $395.3 million and a net loss of $30.7 million. The company expects to initiate the Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies soon. R&D expenses increased to $25.9 million, primarily due to higher personnel costs. Century has reduced its GAAP operating expenses guidance for 2022 to $140 million to $145 million, and forecasts a cash runway into 2025.
Century Therapeutics (NASDAQ: IPSC) will host a virtual Research and Development Day on November 11, 2022, from 8:00 AM to 9:30 AM ET. This event will feature presentations from the management team and Dr. Jonathan Rosenberg from Memorial Sloan Kettering Cancer Center, focused on the company's solid tumor strategy and gamma delta iT cell platform. Preclinical data will also be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting. More details can be found on the company's website under Events & Presentations.
Century Therapeutics (NASDAQ: IPSC) announced that it will present preclinical data from its iPSC-based cell therapy platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting, scheduled for November 8-12, 2022, in Boston. The company will showcase two poster presentations: one focusing on enhancing iNK cell therapies for better anti-tumor efficacy on November 10, and the other on targeting solid tumors with iPSC-derived CAR T cells on November 11. These advancements underline the company's commitment to innovative cancer therapies.